HVTN 095/MTN-022

Phase 1 Safety and Immunogenicity of DNA/NYVAC Prime Boost Vaccination With/Without Emtricitabine/Tenofovir

Protocol Title
A phase 1 clinical trial to evaluate the safety and immunogenicity of DNA/NYVAC prime boost vaccination with or without oral emtricitabine/tenofovir or vaginal tenofovir 1% gel in healthy, HIV-1–uninfected adult female participants
DAIDS Protocol ID
11852
Status
Withdrawn
Countries
South Africa
United States

Source URL: https://mtnstopshiv.org/research/studies/hvtn-095mtn-022